Fig. 1: Response assessment for all 34 patients. | Blood Cancer Journal

Fig. 1: Response assessment for all 34 patients.

From: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Fig. 1: Response assessment for all 34 patients.The alternative text for this image may have been generated using AI.

a Response and MRD were analyzed in all patients and separately for those with mutated IGHV, and those with unmutated IGHV without TP53 aberration. b Progression-free survival and overall survival for all 34 patients. c Subgroup analysis of CR/CRi with BM-uMRD at last follow-up.

Back to article page